These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 17329191

  • 21. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N, Holman MJ, Yang HC.
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [Abstract] [Full Text] [Related]

  • 22. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
    Boucher A, Lord H, Collette S, Morin M, Dandavino R.
    Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
    [Abstract] [Full Text] [Related]

  • 23. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.
    J Infect Dis; 2001 Dec 01; 184(11):1461-4. PubMed ID: 11709790
    [Abstract] [Full Text] [Related]

  • 24. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 01; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 25. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM, Kennedy SE, Rawlinson WD, Mackie FE.
    Pediatr Transplant; 2017 Feb 01; 21(1):. PubMed ID: 27704725
    [Abstract] [Full Text] [Related]

  • 26. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec 01; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 27. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
    Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, van Besien K.
    Bone Marrow Transplant; 2003 May 01; 31(9):813-6. PubMed ID: 12732890
    [Abstract] [Full Text] [Related]

  • 28. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F, Rueda B, Lizasoain M, Juan RS, Folgueira D, Andrés A, Morales JM, Jiménez C, Meneu JC, Aguado JM.
    Transpl Infect Dis; 2009 Oct 01; 11(5):400-4. PubMed ID: 19570139
    [Abstract] [Full Text] [Related]

  • 29. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.
    Bone Marrow Transplant; 1996 Apr 01; 17(4):589-93. PubMed ID: 8722360
    [Abstract] [Full Text] [Related]

  • 30. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F, Losurdo G, Fontana I, Rabagliati AM, Bonatto L, Valente R, Venzano P, Nocera A, Basile GC, Valente U, Gusmano R.
    Transpl Int; 1998 Apr 01; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [Abstract] [Full Text] [Related]

  • 31. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B.
    J Heart Lung Transplant; 2004 Apr 01; 23(4):461-5. PubMed ID: 15063406
    [Abstract] [Full Text] [Related]

  • 32. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Kır O, Zeytinoğlu A, Arda B, Yılmaz M, Aşçı G, Töz H.
    Transplant Proc; 2017 Apr 01; 49(3):537-540. PubMed ID: 28340829
    [Abstract] [Full Text] [Related]

  • 33. Treatment of cytomegalovirus infection after renal transplantation: experience from a single center in China.
    Li Y, Yan H, Xue WJ, Tian PX, Ding XM, Pan XM, Feng XS, Xiang HL, Hou J, Tian XH, Zheng J, Ding CG, Fan P, Liu HB.
    Ann Transplant; 2013 Mar 22; 18():125-35. PubMed ID: 23792512
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients.
    Nafar M, Roshan A, Pour-Reza-Gholi F, Samadian F, Ahmadpoor P, Samavat S, Abbasi MA.
    Iran J Kidney Dis; 2014 May 22; 8(3):231-5. PubMed ID: 24878947
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.